April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Adalimumab (Humira) for the Treatment of Refractory Sight-Threatening Non-Infectious Uveitis: Interim Results of an Open-Label Prospective Multicenter Study
Author Affiliations & Notes
  • E. B. Suhler
    Uveitis Clinic, Casey Eye Institute-OHSU/Portland VAMC, Portland, Oregon
  • C. Y. Lowder
    Cole Eye Inst-Ophthalmology, Cole Eye Institute, Cleveland, Ohio
  • D. A. Goldstein
    Uveitis Clinic, University of Illinois-Chicago, Chicago, Illinois
  • T. R. Giles
    Uveitis Clinic, Casey Eye Institute-OHSU, Portland, Oregon
  • H. H. Tessler
    Department of Ophthalmology, University of Illinois, Gurnee, Illinois
  • A. K. Lauer
    Uveitis Clinic, Casey Eye Institute-OHSU, Portland, Oregon
  • J. R. Smith
    Uveitis Clinic, Casey Eye Institute-OHSU, Portland, Oregon
  • J. T. Rosenbaum
    Uveitis Clinic, Casey Eye Institute-OHSU, Portland, Oregon
  • Footnotes
    Commercial Relationships  E.B. Suhler, Abbott, F; C.Y. Lowder, Abbott, F; D.A. Goldstein, Abbott, F; T.R. Giles, Abbott, F; H.H. Tessler, Abbott, F; A.K. Lauer, Abbott, F; J.R. Smith, Abbott, F; J.T. Rosenbaum, Abbott, F.
  • Footnotes
    Support  Abbott
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2918. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. B. Suhler, C. Y. Lowder, D. A. Goldstein, T. R. Giles, H. H. Tessler, A. K. Lauer, J. R. Smith, J. T. Rosenbaum; Adalimumab (Humira) for the Treatment of Refractory Sight-Threatening Non-Infectious Uveitis: Interim Results of an Open-Label Prospective Multicenter Study. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2918.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : to report the ongoing safety and effectiveness of adalimumab (Humira, Abbott), a fully human monoclonal antibody against TNF-alpha, for the treatment of refractory non-infectious uveitis.

Methods: : Three centers received IRB approval to participate in an open-label, prospective clinical trial utilizing 40 mg subcutaneous injections of adalimumab administered every two weeks for the treatment of non-infectious uveitis refractory to corticosteroids and at least one immunosuppressive. Treatment outcome was ascertained at 10 weeks by a composite clinical endpoint comprised of visual acuity, intraocular inflammation, ability to taper corticosteroids or immunosuppressives, and posterior segment imaging with fluorescein angiography and ocular coherence tomography. Patients who met one or more study endpoints without decrement in any were allowed to continue adalimumab therapy for a total of 50 weeks, when outcome assessments were repeated.

Results: : Enrollment in the study concluded at 31 patients in September 2009. Seventeen of 26 patients reaching the 10 week assessment endpoint (65%) were characterized as clinical responders and allowed to continue in the study. All but two initial responders remain in the study, with three completing 50 weeks successfully, and the remainder still in follow-up. Reasons for study discontinuation after 10 weeks included unintended pregnancy (1) and primary loss of efficacy (1, at week 23). One significant adverse effect, in which a patient was hospitalized in a hypoglycemic coma, required study discontinuation, but was not clearly related to adalimumab. Minor adverse effects included mild infections that required delaying therapy with adalimumab but that did not require study discontinuation.

Conclusions: : Adalimumab was effective in the treatment of 65% of enrolled patients with refractory uveitis at 10 weeks after study enrollment. Although toxicity was uncommon, careful surveillance for serious potential side effects remains important. Ongoing study is required to further classify subsets of patients in whom TNF-alpha blockers in general, and adalimumab specifically, will be safe and effective.

Clinical Trial: : www.clinicaltrials.gov NCT00525902

Keywords: uveitis-clinical/animal model • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • autoimmune disease 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.